From: JAK2 mutation may predict response and guide first line treatment in rheumatoid arthritis
DAS28 | Non-mutant JAK2 | Mutant JAK2 | X | P |
---|---|---|---|---|
Remission (≤ 2.6) (20 patients) | 14 (70%) | 6 (30%) | 9.24 | 0.02 |
Low disease activity (≤ 3.2) (24 patients) | 13 (54.2%) | 11 (45.8%) | ||
Moderate disease activity (3.2–5.1) (15 patients) | 6 (40%) | 9 (60%) | ||
Severe disease activity (> 5.1) (26 patients) | 7 (26.9%) | 19 (73.1%) |